HomeCompareKEM vs KMB

KEM vs KMB: Dividend Comparison 2026

KEM yields 100.14% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KEM wins by $3.87M in total portfolio value
10 years
KEM
KEM
● Live price
100.14%
Share price
$27.58
Annual div
$27.62
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.92M
Annual income
$1,321,930.60
Full KEM calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — KEM vs KMB

📍 KEM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKEMKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KEM + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KEM pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KEM
Annual income on $10K today (after 15% tax)
$8,512.20/yr
After 10yr DRIP, annual income (after tax)
$1,123,641.01/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, KEM beats the other by $1,119,211.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KEM + KMB for your $10,000?

KEM: 50%KMB: 50%
100% KMB50/50100% KEM
Portfolio after 10yr
$1.98M
Annual income
$663,570.96/yr
Blended yield
33.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

KEM
Analyst Ratings
1
Buy
3
Hold
1
Sell
Consensus: Hold
Altman Z
3.0
Piotroski
6/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KEM buys
0
KMB buys
0
No recent congressional trades found for KEM or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKEMKMB
Forward yield100.14%5.25%
Annual dividend / share$27.62$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$3.92M$45.9K
Annual income after 10y$1,321,930.60$5,211.33
Total dividends collected$3.50M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: KEM vs KMB ($10,000, DRIP)

YearKEM PortfolioKEM Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$20,714$10,014.36$11,314$613.68+$9.4KKEM
2$41,551$19,387.01$12,865$759.19+$28.7KKEM
3$80,805$36,344.69$14,709$943.96+$66.1KKEM
4$152,516$66,055.38$16,919$1,180.17+$135.6KKEM
5$279,714$116,521.07$19,588$1,484.33+$260.1KKEM
6$499,012$199,718.26$22,838$1,879.06+$476.2KKEM
7$866,933$332,990.05$26,832$2,395.60+$840.1KKEM
8$1,468,275$540,657.26$31,788$3,077.63+$1.44MKEM
9$2,426,831$855,776.52$38,000$3,986.82+$2.39MKEM
10$3,918,640$1,321,930.60$45,872$5,211.33+$3.87MKEM

KEM vs KMB: Complete Analysis 2026

KEMStock

In order to achieve its investment objective, the fund is actively managed and seeks to mitigate downside risk while attempting to outperform broad emerging markets by dynamically adjusting its allocations between the Underlying ETFs and cash and cash equivalents. Under normal circumstances, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in securities of issuers located in emerging markets, including other investments, such as investment companies, that provide investment exposure to such securities.

Full KEM Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this KEM vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KEM vs SCHDKEM vs JEPIKEM vs OKEM vs KOKEM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.